Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Bullboard Posts
Post by jcjohn36on Jun 12, 2008 9:15am
395 Views
Post# 15176295

nice price on these options

nice price on these options

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options
Wednesday June 11, 6:01 pm ET

LONDON, ONTARIO--(Marketwire - June 11, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT - News) announced today, that at its Board meeting of June 10, 2008 the Board of Directors approved the granting of 335,679 stock options to its eight Directors under the Company's Stock Option Plan as a retainer for their service on the Board and its committees during fiscal 2008. The options vest immediately, have a life of five years and are exercisable at a price of $0.75 per share. The exercise price represents the closing price of the Company's common shares on June 9, 2008, as reported on the TSX Venture Exchange.


"The use of stock options to compensate the board members allows us to conserve our cash as we move forward with our drug development plans and demonstrates the Directors' belief and commitment to the company's future," advised company Chairman and CEO, Mr. John Drake.

Bullboard Posts